{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:26:23Z","timestamp":1790670383657,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10072-025-07987-1","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:09:27Z","timestamp":1736842167000},"page":"2055-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of vortioxetine in different neurological fields: a systematic review and future perspectives"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-7195","authenticated-orcid":false,"given":"Giulio","family":"Verrienti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Raccagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"7987_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jad.2023.01.074","volume":"328","author":"M Adair","year":"2023","unstructured":"Adair M, Christensen MC, Florea I, Loft H, Fagiolini A (2023) Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability. J Affect Disord 328:345\u2013354. https:\/\/doi.org\/10.1016\/j.jad.2023.01.074Epub 2023 Jan 26. PMID: 36708956","journal-title":"J Affect Disord"},{"issue":"6","key":"7987_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ijnp\/pyad018","volume":"26","author":"Z Li","year":"2023","unstructured":"Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, Peng P, Wang Q, Liu Y, Li M, Hao Y, Xu H, He L, Wang Y, Chen S, Liu T (2023) Effectiveness and safety of Vortioxetine for the treatment of major depressive disorder in the Real World: a systematic review and Meta-analysis. Int J Neuropsychopharmacol 26(6):373\u2013384. https:\/\/doi.org\/10.1093\/ijnp\/pyad018PMID: 37105713; PMCID: PMC10289145","journal-title":"Int J Neuropsychopharmacol"},{"key":"7987_CR3","doi-asserted-by":"publisher","first-page":"922648","DOI":"10.3389\/fpsyt.2022.922648","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Cai Y, Hu X, Lu CY, Nie X, Shi L (2022) Systematic review and Meta-analysis of Vortioxetine for the treatment of major depressive disorder in adults. Front Psychiatry 13:922648. https:\/\/doi.org\/10.3389\/fpsyt.2022.922648PMID: 35815048; PMCID: PMC9263295","journal-title":"Front Psychiatry"},{"key":"7987_CR4","doi-asserted-by":"publisher","unstructured":"Stahl SM (2015) Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr.;20(2):93\u2013\u20097. https:\/\/doi.org\/10.1017\/S1092852915000139. PMID: 25831967","DOI":"10.1017\/S1092852915000139"},{"issue":"9","key":"7987_CR5","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"B Bang-Andersen","year":"2011","unstructured":"Bang-Andersen B, Ruhland T, J\u00f8rgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, M\u00f8rk A, Stensb\u00f8l TB (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54(9):3206\u20133221. https:\/\/doi.org\/10.1021\/jm101459gEpub 2011 Apr 12. PMID: 21486038","journal-title":"J Med Chem"},{"issue":"3","key":"7987_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1124\/jpet.111.189068","volume":"340","author":"A M\u00f8rk","year":"2012","unstructured":"M\u00f8rk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, S\u00e1nchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensb\u00f8l TB (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340(3):666\u2013675. https:\/\/doi.org\/10.1124\/jpet.111.189068Epub 2011 Dec 9. PMID: 22171087","journal-title":"J Pharmacol Exp Ther"},{"key":"7987_CR7","unstructured":"Westrich, L., Pehrson, A., Zhong, H., Nielsen, S. M., Frederiksen, K., Stensb\u00f8l, T.B.,\u2026 & Sanchez, C. (2012). In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract, 16(Suppl 1), 47."},{"key":"7987_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43\u201357. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.07.001Epub 2014 Jul 9. PMID: 25016186","journal-title":"Pharmacol Ther"},{"issue":"10","key":"7987_CR9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.euroneuro.2013.01.002","volume":"23","author":"P Stenkrona","year":"2013","unstructured":"Stenkrona P, Halldin C, Lundberg J (2013) 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 23(10):1190\u20131198. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.01.002Epub 2013 Feb 18. PMID: 23428337","journal-title":"Eur Neuropsychopharmacol"},{"key":"7987_CR10","doi-asserted-by":"crossref","unstructured":"Sowa-Ku\u0107ma M, Pa\u0144czyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Stycze\u0144 K, Datka W, Koperny M, Vortioxetine (2017) A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 69(4):595\u2013601 Epub 2017 Feb 1. PMID: 28499187","DOI":"10.1016\/j.pharep.2017.01.030"},{"key":"7987_CR11","doi-asserted-by":"crossref","unstructured":"Stahl SM (2015) Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin\u2019s downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr.;20(4):331-6. doi: 10.1017\/S1092852915000334. Epub 2015 Jun 11. PMID: 26062900","DOI":"10.1017\/S1092852915000334"},{"key":"7987_CR12","doi-asserted-by":"publisher","unstructured":"Morikawa H, Manzoni OJ, Crabbe JC, Williams JT (2000) Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. Mol Pharmacol.;58(6):1271-8. https:\/\/doi.org\/10.1124\/mol.58.6.1271. PMID: 11093763","DOI":"10.1124\/mol.58.6.1271"},{"issue":"12","key":"7987_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/syn.21608","volume":"66","author":"CE Hagan","year":"2012","unstructured":"Hagan CE, McDevitt RA, Liu Y, Furay AR, Neumaier JF (2012) 5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse 66(12):1024\u20131034. https:\/\/doi.org\/10.1002\/syn.21608Epub 2012 Sep 29. PMID: 22961814; PMCID: PMC3472085","journal-title":"Synapse"},{"key":"7987_CR14","doi-asserted-by":"crossref","unstructured":"Tiger M, Varn\u00e4s K, Okubo Y, Lundberg J (2018) The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology (Berl).;235(5):1317\u20131334. doi: 10.1007\/s00213-018-4872-1. Epub 2018 Mar 15. PMID: 29546551; PMCID: PMC5919989","DOI":"10.1007\/s00213-018-4872-1"},{"key":"7987_CR15","doi-asserted-by":"publisher","unstructured":"Anthony JP, Sexton TJ, Neumaier JF (2000) Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci Res.;61(1):82\u2013\u20097. https:\/\/doi.org\/10.1002\/1097-4547(20000701)61:1%3C82::AID-JNR10%3E3.0.CO;2-E PMID: 10861803","DOI":"10.1002\/1097-4547(20000701)61:1%3C82::AID-JNR10%3E3.0.CO;2-E"},{"key":"7987_CR16","doi-asserted-by":"publisher","unstructured":"Hoyer D (2019) Chapter Four - Serotonin receptors nomenclature, Editor(s): Mark D. Tricklebank, Eileen Daly, The Serotonin System, Academic Press, Pages 63\u201393, ISBN 9780128133231. https:\/\/doi.org\/10.1016\/B978-0-12-813323-1.00004-9","DOI":"10.1016\/B978-0-12-813323-1.00004-9"},{"issue":"7","key":"7987_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00210-023-02411-x","volume":"396","author":"S Afshar","year":"2023","unstructured":"Afshar S, Shahidi S, Baooshi H, Hoseini M, Esmaeili M, Hashemi-Firouzi N, Komaki A (2023) The role of hippocampal 5-HT1D and 5-HT1F receptors on learning and memory in rats. Naunyn Schmiedebergs Arch Pharmacol 396(7):1451\u20131460 Epub 2023 Feb 7. PMID: 36749399","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"7987_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/pr.118.015552","volume":"73","author":"NM Barnes","year":"2021","unstructured":"Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villal\u00f3n CM, Vogel H, Watts SW, Hoyer D (2021) International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharmacol Rev 73(1):310\u2013520. https:\/\/doi.org\/10.1124\/pr.118.015552PMID: 33370241; PMCID: PMC7770494","journal-title":"Pharmacol Rev"},{"issue":"6","key":"7987_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/ejn.15623","volume":"55","author":"JV Schweimer","year":"2022","unstructured":"Schweimer JV, Brouard JT, Li Y, S\u00e1nchez C, Sharp T (2022) In vivo electrophysiological study of the targeting of 5-HT3 receptor-expressing cortical interneurons by the multimodal antidepressant, vortioxetine. Eur J Neurosci 55(6):1409\u20131423. https:\/\/doi.org\/10.1111\/ejn.15623Epub 2022 Mar 3. PMID: 35146812; PMCID: PMC9314076","journal-title":"Eur J Neurosci"},{"issue":"5","key":"7987_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1017\/S1092852915000346","volume":"20","author":"SM Stahl","year":"2015","unstructured":"Stahl SM (2015) Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr 20(5):455\u2013459 Epub 2015 Jun 30. PMID: 26122791","journal-title":"CNS Spectr"},{"issue":"3","key":"7987_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1742-7843.2012.00886.x","volume":"111","author":"J Areberg","year":"2012","unstructured":"Areberg J, S\u00f8gaard B, H\u00f8jer AM (2012) The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 111(3):198\u2013205. https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00886.xEpub 2012 Apr 24. PMID: 22448783","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"7987_CR22","doi-asserted-by":"publisher","unstructured":"Krupa AJ, Wojtasik-Bakalarz K, Siwek M Vortioxetine - pharmacological properties and use in mood disorders. The current state of knowledge. Psychiatr Pol 2022 Aug 19:1\u201318. English, Polish. https:\/\/doi.org\/10.12740\/PP\/OnlineFirst\/151570. Epub ahead of print. PMID: 36571300.","DOI":"10.12740\/PP\/OnlineFirst\/151570"},{"issue":"10","key":"7987_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","volume":"33","author":"G Chen","year":"2013","unstructured":"Chen G, Lee R, H\u00f8jer AM, Buchbjerg JK, Serenko M, Zhao Z (2013) Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 33(10):727\u2013736. https:\/\/doi.org\/10.1007\/s40261-013-0117-6PMID: 23975654; PMCID: PMC3775155","journal-title":"Clin Drug Investig"},{"key":"7987_CR24","doi-asserted-by":"crossref","unstructured":"Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A (2021) Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry.;109:110266. doi: 10.1016\/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697","DOI":"10.1016\/j.pnpbp.2021.110266"},{"key":"7987_CR25","doi-asserted-by":"publisher","unstructured":"Andrade C, Sandarsh S, Chethan KB, Nagesh KS (2010) Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry.;71(12):1565-75. https:\/\/doi.org\/10.4088\/JCP.09r05786blu. PMID: 21190637","DOI":"10.4088\/JCP.09r05786blu"},{"issue":"1","key":"7987_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12911-023-02206-3","volume":"23","author":"J Goyal","year":"2023","unstructured":"Goyal J, Ng DQ, Zhang K, Chan A, Lee J, Zheng K, Hurley-Kim K, Nguyen L, He L, Nguyen M, McBane S, Li W, Cadiz CL (2023) Using machine learning to develop a clinical prediction model for SSRI-associated bleeding: a feasibility study. BMC Med Inf Decis Mak 23(1):105. https:\/\/doi.org\/10.1186\/s12911-023-02206-3PMID: 37301967; PMCID: PMC10257821","journal-title":"BMC Med Inf Decis Mak"},{"key":"7987_CR27","doi-asserted-by":"publisher","unstructured":"Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA (2016) The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom.;85(5):270\u2013\u200988. https:\/\/doi.org\/10.1159\/000447034. Epub 2016 Aug 11. PMID: 27508501","DOI":"10.1159\/000447034"},{"issue":"18","key":"7987_CR28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1212\/WNL.0b013e318271f848","volume":"79","author":"DG Hackam","year":"2012","unstructured":"Hackam DG, Mrkobrada M (2012) Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 79(18):1862\u20131865. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f848Epub 2012 Oct 17. PMID: 23077009","journal-title":"Neurology"},{"issue":"1","key":"7987_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1136\/eb-2015-102212","volume":"19","author":"R Morriss","year":"2016","unstructured":"Morriss R (2016) Antidepressants are associated with hospital admitted intracranial bleeds in people taking other medication associated with bleeding. Evid Based Ment Health 19(1):24. https:\/\/doi.org\/10.1136\/eb-2015-102212Epub 2016 Jan 7. PMID: 26744424","journal-title":"Evid Based Ment Health"},{"key":"7987_CR30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71PMID: 33782057; PMCID: PMC8005924","journal-title":"BMJ"},{"key":"7987_CR31","doi-asserted-by":"publisher","unstructured":"Santos Garc\u00eda D, Alonso Losada MG, Cimas Hernando I, Cabo L\u00f3pez I, Y\u00e1\u00f1ez Ba\u00f1a R, Alonso Redondo R, Paz Gonz\u00e1lez JM, Cores Bartolom\u00e9 C, Feal Painceiras MJ, \u00cd\u00f1iguez, Alvarado MC, Labandeira C (2022) Garc\u00eda D\u00edaz I. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson\u2019s Disease Patients with Major Depression: An Open-Label Prospective Study. Brain Sci.;12(11):1466. https:\/\/doi.org\/10.3390\/brainsci12111466. PMID: 36358393; PMCID: PMC9688230","DOI":"10.3390\/brainsci12111466"},{"key":"7987_CR32","doi-asserted-by":"publisher","unstructured":"Gamberini G, Masuccio FG, Ferriero G, Cattaneo D, Solaro C (2021) Safety and efficacy of vortioxetine on depressive symptoms and cognition in post-stroke patients: a pilot study. J Affect Disord.;286:108\u2013109. https:\/\/doi.org\/10.1016\/j.jad.2021.02.075. Epub 2021 Mar 4. PMID: 33714170","DOI":"10.1016\/j.jad.2021.02.075"},{"key":"7987_CR33","doi-asserted-by":"publisher","unstructured":"Cumbo E, Cumbo S, Torregrossa S, Migliore D (2019) Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer\u2019s Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study. J Prev Alzheimers Dis.;6(3):192\u2013197. https:\/\/doi.org\/10.14283\/jpad.2019.24. PMID: 31062834","DOI":"10.14283\/jpad.2019.24"},{"issue":"6","key":"7987_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/YIC.0000000000000376","volume":"36","author":"SN Tan","year":"2021","unstructured":"Tan SN, Tan C (2021) Vortioxetine improves cognition in mild cognitive impairment. Int Clin Psychopharmacol 36(6):279\u2013287. https:\/\/doi.org\/10.1097\/YIC.0000000000000376PMID: 34282748; PMCID: PMC8483775","journal-title":"Int Clin Psychopharmacol"},{"key":"7987_CR35","doi-asserted-by":"publisher","unstructured":"Lenze EJ, Stevens A, Waring JD, Pham VT, Haddad R, Shimony J, Miller JP, Bowie CR (2020) Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial. Am J Psychiatry.;177(6):548\u2013555. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19050561. Epub 2020 Mar 26. Erratum in: Am J Psychiatry. 2020;177(6):556. PMID: 32212856; PMCID: PMC7560967","DOI":"10.1176\/appi.ajp.2019.19050561"},{"key":"7987_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jad.2023.06.024","volume":"338","author":"MC Christensen","year":"2023","unstructured":"Christensen MC, Schmidt SN, Grande I (2023) Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: the MEMORY study. J Affect Disord 338:423\u2013431. https:\/\/doi.org\/10.1016\/j.jad.2023.06.024Epub 2023 Jun 12. PMID: 37315590","journal-title":"J Affect Disord"},{"key":"7987_CR37","doi-asserted-by":"publisher","unstructured":"Padovani A, Caratozzolo S, Benussi A, Galli A, Rozzini L, Cosseddu M, Turrone R, Pilotto A (2024) Vortioxetine Treatment for Depression in Patients with Prodromal vs Mild Alzheimer\u2019s Disease: A Six-Month, Open-Label, Observational Study. J Prev Alzheimers Dis.;11(2):375\u2013381. https:\/\/doi.org\/10.14283\/jpad.2023.132. PMID: 38374744","DOI":"10.14283\/jpad.2023.132"},{"issue":"2","key":"7987_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.9758\/cpn.2022.20.2.311","volume":"20","author":"HW Jeong","year":"2022","unstructured":"Jeong HW, Yoon KH, Lee CH, Moon YS, Kim DH (2022) Vortioxetine Treatment for Depression in Alzheimer\u2019s Disease: a Randomized, Double-blind, placebo-controlled study. Clin Psychopharmacol Neurosci 20(2):311\u2013319 PMID: 35466102; PMCID: PMC9048008","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"7987_CR39","doi-asserted-by":"publisher","unstructured":"Kirksey A, Meghan C, Haskins S, Cheng J, Liu S, Spencer Modified Jadad Scale. PLOS ONE., Fig.\u00a0(2015) https:\/\/doi.org\/10.1371\/journal.pone.0137312.g002","DOI":"10.1371\/journal.pone.0137312.g002"},{"key":"7987_CR40","unstructured":"https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools accessed on 12.07.2024"},{"issue":"2","key":"7987_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/brainsci13020318","volume":"13","author":"J Pagonabarraga","year":"2023","unstructured":"Pagonabarraga J, \u00c1lamo C, Castellanos M, D\u00edaz S, Manzano S (2023) Depression in Major Neurodegenerative diseases and strokes: a critical review of similarities and differences among neurological disorders. Brain Sci 13(2):318. https:\/\/doi.org\/10.3390\/brainsci13020318PMID: 36831861; PMCID: PMC9954482","journal-title":"Brain Sci"},{"key":"7987_CR42","doi-asserted-by":"publisher","unstructured":"Paolucci S (2017) Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother.;18(10):1011\u20131017. https:\/\/doi.org\/10.1080\/14656566.2017.1334765. Epub 2017 Jun 5. PMID: 28535081","DOI":"10.1080\/14656566.2017.1334765"},{"key":"7987_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1745017901511010144","volume":"11","author":"MG Carta","year":"2015","unstructured":"Carta MG, Pala AN, Finco G, Musu M, Moro MF (2015) Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 11:144\u2013149. https:\/\/doi.org\/10.2174\/1745017901511010144PMID: 25893002; PMCID: PMC4397833","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"7987_CR44","volume-title":"Beck Depression Inventory Manual","author":"A Beck","year":"1996","unstructured":"Beck A, Steer R, Brown GBDI-II (1996) Beck Depression Inventory Manual, 2nd edn. Psychological Corporation, San Antonio, TX, USA","edition":"2"},{"key":"7987_CR45","doi-asserted-by":"publisher","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc.;53(4):695-9. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019;67(9):1991. doi: 10.1111\/jgs.15925. PMID: 15817019","DOI":"10.1111\/j.1532-5415"},{"key":"7987_CR46","doi-asserted-by":"publisher","first-page":"119865","DOI":"10.1016\/j.lfs.2021.119865","volume":"283","author":"AM Emam","year":"2021","unstructured":"Emam AM, Saad MA, Ahmed NA, Zaki HF (2021) Vortioxetine mitigates neuronal damage by restricting PERK\/eIF2\u03b1\/ATF4\/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Life Sci 283:119865. https:\/\/doi.org\/10.1016\/j.lfs.2021.119865Epub 2021 Aug 4. PMID: 34358549","journal-title":"Life Sci"},{"key":"7987_CR47","doi-asserted-by":"publisher","unstructured":"Li Y, Zhu H, Yang J, Ke K, Zhu Y, Chen L, Qu Y, Suo R, Chen X, Zhu Y (2019) Discovering Proangiogenic Drugs in Ischemic Stroke Based on the Relationship between Protein Domain and Drug Substructure. ACS Chem Neurosci.;10(1):507\u2013517. https:\/\/doi.org\/10.1021\/acschemneuro.8b00381. Epub 2018 Oct 29. Erratum in: ACS Chem Neurosci. 2022;13(14):2236\u20132237. PMID: 30346717","DOI":"10.1021\/acschemneuro.8b00381"},{"issue":"5","key":"7987_CR48","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1161\/STROKEAHA.114.007642","volume":"46","author":"J Adamczak","year":"2015","unstructured":"Adamczak J, Hoehn M (2015) Poststroke angiogenesis, con: dark side of angiogenesis. Stroke 46(5):e103\u2013e104. https:\/\/doi.org\/10.1161\/STROKEAHA.114.007642Epub 2015 Mar 26. PMID: 25813195","journal-title":"Stroke"},{"issue":"5","key":"7987_CR49","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1161\/STROKEAHA.114.007641","volume":"46","author":"DA Greenberg","year":"2015","unstructured":"Greenberg DA (2015) Poststroke angiogenesis, pro: making the desert bloom. Stroke 46(5):e101\u2013e102. https:\/\/doi.org\/10.1161\/STROKEAHA.114.007641Epub 2015 Mar 26. PMID: 25813196; PMCID: PMC4414879","journal-title":"Stroke"},{"issue":"11","key":"7987_CR50","doi-asserted-by":"publisher","first-page":"CD009286","DOI":"10.1002\/14651858.CD009286.pub4","volume":"11","author":"LA Legg","year":"2021","unstructured":"Legg LA, Rudberg AS, Hua X, Wu S, Hackett ML, Tilney R, Lindgren L, Kutlubaev MA, Hsieh CF, Barugh AJ, Hankey GJ, Lundstr\u00f6m E, Dennis M, Mead GE (2021) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 11(11):CD009286. https:\/\/doi.org\/10.1002\/14651858.CD009286.pub4PMID: 34780067; PMCID: PMC8592088","journal-title":"Cochrane Database Syst Rev"},{"key":"7987_CR51","doi-asserted-by":"publisher","unstructured":"Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol.;6(4):278\u2013\u200996. https:\/\/doi.org\/10.1111\/j.2044-8260.1967.tb00530.x. PMID: 6080235","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"issue":"6","key":"7987_CR52","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/cells12060837","volume":"12","author":"C Budrow","year":"2023","unstructured":"Budrow C, Elder K, Coyle M, Centner A, Lipari N, Cohen S, Glinski J, Kinzonzi N, Wheelis E, McManus G, Manfredsson F, Bishop C (2023) Broad serotonergic actions of Vortioxetine as a Promising Avenue for the treatment of L-DOPA-Induced Dyskinesia. Cells 12(6):837. https:\/\/doi.org\/10.3390\/cells12060837PMID: 36980178; PMCID: PMC10047495","journal-title":"Cells"},{"issue":"6","key":"7987_CR53","doi-asserted-by":"publisher","first-page":"e15750","DOI":"10.7759\/cureus.15750","volume":"13","author":"R Yoshimura","year":"2021","unstructured":"Yoshimura R, Ikenouchi A, Okamoto N, Konishi Y (2021) Vortioxetine Improved Depressive State in Parkinson\u2019s Disease. Cureus 13(6):e15750. https:\/\/doi.org\/10.7759\/cureus.15750PMID: 34290929; PMCID: PMC8289392","journal-title":"Cureus"},{"key":"7987_CR54","doi-asserted-by":"publisher","unstructured":"Ag\u00fcera-Ortiz L, Garc\u00eda-Ramos R, Grandas P\u00e9rez FJ, L\u00f3pez-\u00c1lvarez J, Montes Rodr\u00edguez JM, Olazar\u00e1n Rodr\u00edguez FJ, Olivera Pueyo J, Pelegr\u00edn Valero C, Porta-Etessam J (2021) Focus on Depression in Parkinson\u2019s Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics.Parkinsons Dis. 2021:6621991. https:\/\/doi.org\/10.1155\/2021\/6621991. PMID: 33628415; PMCID: PMC7884180","DOI":"10.1155\/2021\/6621991"},{"key":"7987_CR55","doi-asserted-by":"publisher","unstructured":"Smith S, Sergio J, Coyle M, Elder K, Centner A, Cohen S, Terry M, Lipari N, Glinski J, Wheelis E, Budrow C, Bishop C (2022) The effects of Vilazodone, YL0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology (Berl).;239(7):2119\u20132132. https:\/\/doi.org\/10.1007\/s00213-022-06078-9. Epub 2022 Mar 11. PMID: 35275226","DOI":"10.1007\/s00213-022-06078-9"},{"key":"7987_CR56","doi-asserted-by":"publisher","first-page":"108977","DOI":"10.1016\/j.neuropharm.2022.108977","volume":"208","author":"D Nemutlu Samur","year":"2022","unstructured":"Nemutlu Samur D, Ak\u00e7ay G, Y\u0131ld\u0131r\u0131m S, \u00d6zkan A, \u00c7eker T, Derin N, Tanr\u0131\u00f6ver G, Aslan M, A\u011far A, \u00d6zbey G (2022) Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson\u2019s disease via targeting TLR-2 mediated neuroinflammation. Neuropharmacology 208:108977 Epub 2022 Jan 26. PMID: 35092748","journal-title":"Neuropharmacology"},{"issue":"3","key":"7987_CR57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.9758\/cpn.22.1021","volume":"21","author":"YH Al\u0131c\u0131","year":"2023","unstructured":"Al\u0131c\u0131 YH, Kumcu MK (2023) Potential effect of Vortioxetine on Restless Leg Syndrome. Clin Psychopharmacol Neurosci 21(3):599\u2013603. https:\/\/doi.org\/10.9758\/cpn.22.1021PMID: 37424427; PMCID: PMC10335914","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"7987_CR58","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","volume":"20","author":"A Revet","year":"2020","unstructured":"Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH (2020) Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 20(1):308. https:\/\/doi.org\/10.1186\/s12888-020-02711-zPMID: 32546134; PMCID: PMC7298955","journal-title":"BMC Psychiatry"},{"issue":"4","key":"7987_CR59","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00213-020-05452-9","volume":"237","author":"LX Jiang","year":"2020","unstructured":"Jiang LX, Huang GD, Su F, Wang H, Zhang C, Yu X (2020) Vortioxetine administration attenuates cognitive and synaptic deficits in 5\u00d7FAD mice. Psychopharmacology 237(4):1233\u20131243. https:\/\/doi.org\/10.1007\/s00213-020-05452-9Epub 2020 Jan 18. PMID: 31953648","journal-title":"Psychopharmacology"},{"key":"7987_CR60","doi-asserted-by":"publisher","first-page":"809541","DOI":"10.3389\/fphar.2021.809541","volume":"12","author":"G Caruso","year":"2021","unstructured":"Caruso G, Grasso M, Fidilio A, Torrisi SA, Musso N, Geraci F, Tropea MR, Privitera A, Tascedda F, Puzzo D, Salomone S, Drago F, Leggio GM, Caraci F (2021) Antioxidant activity of Fluoxetine and Vortioxetine in a non-transgenic animal model of Alzheimer\u2019s Disease. Front Pharmacol 12:809541. https:\/\/doi.org\/10.3389\/fphar.2021.809541PMID: 35002742; PMCID: PMC8740153","journal-title":"Front Pharmacol"},{"key":"7987_CR61","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3389\/fphar.2019.00693","volume":"10","author":"SA Torrisi","year":"2019","unstructured":"Torrisi SA, Geraci F, Tropea MR, Grasso M, Caruso G, Fidilio A, Musso N, Sanfilippo G, Tascedda F, Palmeri A, Salomone S, Drago F, Puzzo D, Leggio GM, Caraci F (2019) Fluoxetine and Vortioxetine Reverse Depressive-Like phenotype and Memory deficits Induced by A\u03b21\u201342 oligomers in mice: a key role of transforming growth Factor-\u03b21. Front Pharmacol 10:693. https:\/\/doi.org\/10.3389\/fphar.2019.00693PMID: 31293421; PMCID: PMC6598642","journal-title":"Front Pharmacol"},{"key":"7987_CR62","doi-asserted-by":"crossref","unstructured":"M\u00f8rk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C, Vortioxetine (2013) (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav.;105:41\u201350. doi: 10.1016\/j.pbb.2013.01.019. Epub 2013 Feb 1. PMID: 23380522","DOI":"10.1016\/j.pbb.2013.01.019"},{"issue":"1","key":"7987_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.euroneuro.2013.07.001","volume":"24","author":"KG du Jardin","year":"2014","unstructured":"du Jardin KG, Jensen JB, Sanchez C, Pehrson AL (2014) Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 24(1):160\u2013171 Epub 2013 Aug 2. PMID: 23916504","journal-title":"Eur Neuropsychopharmacol"},{"key":"7987_CR64","doi-asserted-by":"crossref","unstructured":"Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C, Pehrson AL (2014) Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol.;24(1):148\u2013\u200959. doi: 10.1016\/j.euroneuro.2013.10.011. Epub 2013 Nov 4. PMID: 24284262","DOI":"10.1016\/j.euroneuro.2013.10.011"},{"key":"7987_CR65","doi-asserted-by":"crossref","unstructured":"Wallace A, Pehrson AL, S\u00e1nchez C, Morilak DA (2014) Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol.;17(10):1695\u2013\u2009706. doi: 10.1017\/S1461145714000571. Epub 2014 May 23. PMID: 24852131; PMCID: PMC4162520","DOI":"10.1017\/S1461145714000571"},{"key":"7987_CR66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pnpbp.2014.12.002","volume":"58","author":"C B\u00e9try","year":"2015","unstructured":"B\u00e9try C, Eti\u00e9vant A, Pehrson A, S\u00e1nchez C, Haddjeri N (2015) Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Prog Neuropsychopharmacol Biol Psychiatry 58:38\u201346 Epub 2014 Dec 16. PMID: 25524057","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"7987_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pbb.2015.05.013","volume":"135","author":"Y Li","year":"2015","unstructured":"Li Y, Abdourahman A, Tamm JA, Pehrson AL, S\u00e1nchez C, Gulinello M (2015) Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. Pharmacol Biochem Behav 135:70\u201382 Epub 2015 Jun 2. PMID: 26046533","journal-title":"Pharmacol Biochem Behav"},{"issue":"14","key":"7987_CR68","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s00213-016-4327-5","volume":"233","author":"KG du Jardin","year":"2016","unstructured":"du Jardin KG, Liebenberg N, M\u00fcller HK, Elfving B, Sanchez C, Wegener G (2016) Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. Psychopharmacology 233(14):2813\u20132825 Epub 2016 May 28. PMID: 27236785","journal-title":"Psychopharmacology"},{"issue":"3","key":"7987_CR69","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1124\/jpet.116.233924","volume":"358","author":"AL Pehrson","year":"2016","unstructured":"Pehrson AL, Hillhouse TM, Haddjeri N, Rovera R, Porter JH, M\u00f8rk A, Smagin G, Song D, Budac D, Cajina M, Sanchez C (2016) Task- and treatment length-dependent effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and hippocampal extracellular acetylcholine in rats. J Pharmacol Exp Ther 358(3):472\u2013482. https:\/\/doi.org\/10.1124\/jpet.116.233924Epub 2016 Jul 11. PMID: 27402279; PMCID: PMC4998672","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"7987_CR70","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/ijnp\/pyw105","volume":"20","author":"L Hatherall","year":"2017","unstructured":"Hatherall L, S\u00e1nchez C, Morilak DA (2017) Chronic vortioxetine treatment reduces exaggerated expression of conditioned fear memory and restores active coping behavior in chronically stressed rats. Int J Neuropsychopharmacol 20(4):316\u2013323. https:\/\/doi.org\/10.1093\/ijnp\/pyw105PMID: 27927740; PMCID: PMC5409129","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"7987_CR71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ijnp\/pyx004","volume":"20","author":"Y Li","year":"2017","unstructured":"Li Y, Sanchez C, Gulinello M (2017) Distinct antidepressant-like and Cognitive effects of antidepressants with different mechanisms of action in Middle-aged female mice. Int J Neuropsychopharmacol 20(6):510\u2013515. https:\/\/doi.org\/10.1093\/ijnp\/pyx004PMID: 28158336; PMCID: PMC5458342","journal-title":"Int J Neuropsychopharmacol"},{"key":"7987_CR72","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fphar.2018.00162","volume":"9","author":"AL Pehrson","year":"2018","unstructured":"Pehrson AL, Pedersen CS, T\u00f8lb\u00f8l KS, Sanchez C (2018) Vortioxetine Treatment reverses Subchronic PCP Treatment-Induced cognitive impairments: a potential role for serotonin receptor-mediated regulation of GABA neurotransmission. Front Pharmacol 9:162. https:\/\/doi.org\/10.3389\/fphar.2018.00162PMID: 29559911; PMCID: PMC5845537","journal-title":"Front Pharmacol"},{"key":"7987_CR73","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fphar.2018.00204","volume":"9","author":"D Felice","year":"2018","unstructured":"Felice D, Guilloux JP, Pehrson A, Li Y, Mendez-David I, Gardier AM, Sanchez C, David DJ (2018) Vortioxetine improves context discrimination in mice through a neurogenesis independent mechanism. Front Pharmacol 9:204. https:\/\/doi.org\/10.3389\/fphar.2018.00204PMID: 29593535; PMCID: PMC5857583","journal-title":"Front Pharmacol"},{"key":"7987_CR74","doi-asserted-by":"publisher","unstructured":"Levada OA, Troyan AS (2019) Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. J Affect Disord.;250:114\u2013122. https:\/\/doi.org\/10.1016\/j.jad.2019.03.040. Epub 2019 Mar 5. PMID: 30852363","DOI":"10.1016\/j.jad.2019.03.040"},{"issue":"10","key":"7987_CR75","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1017\/S1461145714000546","volume":"17","author":"RS McIntyre","year":"2014","unstructured":"McIntyre RS, Lophaven S, Olsen CK (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 17(10):1557\u20131567","journal-title":"Int J Neuropsychopharmacol"},{"key":"7987_CR76","doi-asserted-by":"publisher","unstructured":"Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSA, Randomized, Placebo-Controlled A-R (2015) Double-Blind, FlexibleDose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology.;40(8):2025-37. https:\/\/doi.org\/10.1038\/npp.2015.52. Epub 2015 Feb 17. Erratum in: Neuropsychopharmacology. 2016;41(12):2961. PMID: 25687662; PMCID: PMC4839526","DOI":"10.1038\/npp.2015.52"},{"issue":"4","key":"7987_CR77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","volume":"27","author":"C Katona","year":"2012","unstructured":"Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27(4):215\u2013223. https:\/\/doi.org\/10.1097\/YIC.0b013e3283542457PMID: 22572889","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"7987_CR78","doi-asserted-by":"publisher","first-page":"815","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_160_23","volume":"65","author":"CK Manna","year":"2023","unstructured":"Manna CK, Ranjan R, Kumar P, Ahmad S, Nath S (2023) Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: a randomized-controlled trial. Indian J Psychiatry 65(8):815\u2013824. https:\/\/doi.org\/10.4103\/indianjpsychiatry.indianjpsychiatry_160_23Epub 2023 Aug 7. PMID: 37736222; PMCID: PMC10510634","journal-title":"Indian J Psychiatry"},{"key":"7987_CR79","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jad.2017.12.056","volume":"229","author":"BT Baune","year":"2018","unstructured":"Baune BT, Sluth LB, Olsen CK (2018) The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a shortterm, randomized, double-blind, exploratory study. J Affect Disord 229:421\u2013428. https:\/\/doi.org\/10.1016\/j.jad.2017.12.056Epub 2017 Dec 28. PMID: 29331703","journal-title":"J Affect Disord"},{"issue":"2","key":"7987_CR80","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/pcn.12956","volume":"74","author":"T Inoue","year":"2020","unstructured":"Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I (2020) Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci 74(2):140\u2013148. https:\/\/doi.org\/10.1111\/pcn.12956Epub 2019 Dec 18. PMID: 31725942; PMCID: PMC7027855","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"7987_CR81","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/mp.2017.104","volume":"23","author":"J Smith","year":"2018","unstructured":"Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, Olsen CK, Christensen SR, Dawson GR, Deakin JF, Hawkins P, Morris R, Goodwin G, Harmer CJ (2018) Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 23(5):1127\u20131133. https:\/\/doi.org\/10.1038\/mp.2017.104Epub 2017 May 23. PMID: 28533517; PMCID: PMC5984095","journal-title":"Mol Psychiatry"},{"key":"7987_CR82","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lai S, Zhang J, Wang Y, Zhao H, He J, Huang D, Chen G, Qi Z, Chen P, Yan S, Huang X, Lu X, Zhong S, Jia Y (2024) The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study. J Affect Disord.;351:799\u2013807. doi: 10.1016\/j.jad.2024.01.272. Epub 2024 Feb 3. PMID: 38311073","DOI":"10.1016\/j.jad.2024.01.272"},{"issue":"12","key":"7987_CR83","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ijnp\/pyac054","volume":"25","author":"IC Huang","year":"2022","unstructured":"Huang IC, Chang TS, Chen C, Sung JY (2022) Effect of Vortioxetine on cognitive impairment in patients with major depressive disorder: a systematic review and Meta-analysis of Randomized controlled trials. Int J Neuropsychopharmacol 25(12):969\u2013978. https:\/\/doi.org\/10.1093\/ijnp\/pyac054PMID: 35981958; PMCID: PMC9743961","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"7987_CR84","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00005053-194004000-00075","volume":"91","author":"D Wechsler","year":"1940","unstructured":"Wechsler D (1940) The measurement of adult intelligence. J Nerv Ment Dis 91(4):548","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"7987_CR85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1017\/S1092852913000643","volume":"21","author":"SE Fehnel","year":"2016","unstructured":"Fehnel SE, Forsyth BH, DiBenedetti DB, Danchenko N, Fran\u00e7ois C, Brevig T (2016) Patient-centered assessment of cognitive symptoms of depression. CNS Spectr 21(1):43\u201352 Epub 2013 Sep 25. PMID: 24067243","journal-title":"CNS Spectr"},{"issue":"4","key":"7987_CR86","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M (1979) A New Depression Scale designed to be sensitive to change. Br J Psychiatry 134(4):382\u2013389. https:\/\/doi.org\/10.1192\/bjp.134.4.382","journal-title":"Br J Psychiatry"},{"key":"7987_CR87","doi-asserted-by":"crossref","unstructured":"Lozupone M, La Montagna M, D\u2019Urso F, Piccininni C, Sardone R, Dibello V, Giannelli G, Solfrizzi V, Greco A, Daniele A, Quaranta N, Seripa D, Bellomo A, Logroscino G, Panza F (2018) Pharmacotherapy for the treatment of depression in patients with alzheimer\u2019s disease: a treatment-resistant depressive disorder. Expert Opin Pharmacother.;19(8):823\u2013842. doi: 10.1080\/14656566.2018.1471136. Epub 2018 May 4. PMID: 29726758","DOI":"10.1080\/14656566.2018.1471136"},{"key":"7987_CR88","doi-asserted-by":"publisher","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol.;13(6):614\u2013\u200929. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014;13(8):757. PMID: 24849862","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"7987_CR89","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018PMID: 29653606; PMCID: PMC5958625","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"7987_CR90","doi-asserted-by":"publisher","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.;12(3):189\u2013\u200998. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6. PMID: 1202204","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"7987_CR91","doi-asserted-by":"crossref","unstructured":"Sheikh JI, Yesavage JA Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontologist: J Aging Mental Health Published online 1986.","DOI":"10.1300\/J018v05n01_09"},{"key":"7987_CR92","doi-asserted-by":"publisher","unstructured":"Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology.;48(5 Suppl 6):S10-6. https:\/\/doi.org\/10.1212\/wnl.48.5_suppl_6.10s. PMID: 9153155","DOI":"10.1212\/wnl.48.5_suppl_6.10s"},{"key":"7987_CR93","doi-asserted-by":"crossref","unstructured":"Lawton MP, Brody EM (1969) Autumn;9(3):179\u2013\u200986 Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. PMID: 5349366","DOI":"10.1093\/geront\/9.3_Part_1.179"},{"key":"7987_CR94","doi-asserted-by":"publisher","first-page":"1037816","DOI":"10.3389\/fnagi.2022.1037816","volume":"14","author":"E Cumbo","year":"2023","unstructured":"Cumbo E, Adair M, \u00c5strom DO, Christensen MC (2023) Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer\u2019s disease in routine clinical practice: an analysis of a post-marketing surveillance study in South Korea. Front Aging Neurosci 14:1037816. https:\/\/doi.org\/10.3389\/fnagi.2022.1037816PMID: 36698860; PMCID: PMC9868833","journal-title":"Front Aging Neurosci"},{"key":"7987_CR95","doi-asserted-by":"publisher","unstructured":"Alexopoulos GS, Abrams RC, Young RC, Shamoian CA (1988) Cornell Scale for Depression in Dementia. Biol Psychiatry.;23(3):271\u2013\u200984. https:\/\/doi.org\/10.1016\/0006-3223(88)90038-8. PMID: 3337862","DOI":"10.1016\/0006-3223(88)90038-8"},{"key":"7987_CR96","doi-asserted-by":"publisher","unstructured":"Bae JN, Cho MJ (2004) Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients. J Psychosom Res.;57(3):297\u2013305. https:\/\/doi.org\/10.1016\/j.jpsychores.2004.01.004. PMID: 15507257","DOI":"10.1016\/j.jpsychores.2004.01.004"},{"key":"7987_CR97","doi-asserted-by":"publisher","first-page":"P47","DOI":"10.1093\/geronb\/57.1.P47","volume":"57","author":"JH Lee","year":"2002","unstructured":"Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH et al (2002) Development of the Korean version of the Consortium to establish a Registry for Alzheimer\u2019s Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci 57:P47\u2013P53. https:\/\/doi.org\/10.1093\/geronb\/57.1.P47","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"7987_CR98","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01688638008403793","volume":"2","author":"JC Borod","year":"1980","unstructured":"Borod JC, Goodglass H, Kaplan E (1980) Normative data on the boston diagnostic aphasia examination, parietal lobe battery, and the boston naming test. J Clin Neuropsychol 2:209\u2013215. https:\/\/doi.org\/10.1080\/01688638008403793","journal-title":"J Clin Neuropsychol"},{"key":"7987_CR99","unstructured":"Kang Y Korean Dementia Association editor. Current research in dementia. The Korean Dementia Association; Seoul: 1998. Samsung neuropsychological screening battery; pp. 99\u2013107"},{"issue":"12","key":"7987_CR100","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1007\/s10072-023-06891-w","volume":"44","author":"A Padovani","year":"2023","unstructured":"Padovani A, Antonini A, Barone P, Bellelli G, Fagiolini A, Ferini Strambi L, Sorbi S, Stocchi F (2023) Exploring depression in Alzheimer\u2019s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management. Neurol Sci 44(12):4323\u20134332. https:\/\/doi.org\/10.1007\/s10072-023-06891-wEpub 2023 Jul 4. PMID: 37402937; PMCID: PMC10641046","journal-title":"Neurol Sci"},{"key":"7987_CR101","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC (2017) Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. J Clin Psychiatry.;78(1):115\u2013121. https:\/\/doi.org\/10.4088\/JCP.16m10744. PMID: 27780334","DOI":"10.4088\/JCP.16m10744"},{"issue":"6","key":"7987_CR102","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1017\/S1355617714000241","volume":"20","author":"RK Heaton","year":"2014","unstructured":"Heaton RK, Akshoomoff N, Tulsky D, Mungas D, Weintraub S, Dikmen S, Beaumont J, Casaletto KB, Conway K, Slotkin J, Gershon R (2014) Reliability and validity of composite scores from the NIH Toolbox Cognition Battery in adults. J Int Neuropsychol Soc 20(6):588\u2013598 Epub 2014 Jun 24. PMID: 24960398; PMCID: PMC4103963","journal-title":"J Int Neuropsychol Soc"},{"key":"7987_CR103","doi-asserted-by":"publisher","unstructured":"Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology.;43(11):2412-4. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a. PMID: 8232972","DOI":"10.1212\/wnl.43.11.2412-a"},{"issue":"10","key":"7987_CR104","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jamda.2016.06.020","volume":"17","author":"M Canevelli","year":"2016","unstructured":"Canevelli M, Grande G, Lacorte E, Quarchioni E, Cesari M, Mariani C, Bruno G, Vanacore N (2016) Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and Meta-analysis. J Am Med Dir Assoc 17(10):943\u2013948. https:\/\/doi.org\/10.1016\/j.jamda.2016.06.020Epub 2016 Aug 5. PMID: 27502450","journal-title":"J Am Med Dir Assoc"},{"key":"7987_CR105","doi-asserted-by":"publisher","first-page":"204512532110267","DOI":"10.1177\/20451253211026796","volume":"11","author":"MM Bishop","year":"2021","unstructured":"Bishop MM, Fixen DR, Linnebur SA, Pearson SM (2021) Cognitive effects of vortioxetine in older adults: a systematic review. Ther Adv Psychopharmacol 11:20451253211026796. https:\/\/doi.org\/10.1177\/20451253211026796PMID: 35186260; PMCID: PMC8851129","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-07987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-07987-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-07987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:57:10Z","timestamp":1744804630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-07987-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7987"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-07987-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Giulio Verrienti, Isabella Colonna and Cecilia Raccagni declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}